Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
- DOI
- 10.1016/s2213-8587(22)00008-0
- Published
- 2022 Mar
- Container
- The lancet. Diabetes & endocrinology
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-8587-22-00008-0,
title = {Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.},
author = {Kadowaki T and Isendahl J and Khalid U and Lee SY and Nishida T and Ogawa W and Tobe K and Yamauchi T and Lim S and STEP 6 investigators},
year = {2022},
journal = {The lancet. Diabetes \& endocrinology},
doi = {10.1016/s2213-8587(22)00008-0},
url = {https://doi.org/10.1016/s2213-8587(22)00008-0}
}RIS
TY - JOUR TI - Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. AU - Kadowaki T AU - Isendahl J AU - Khalid U AU - Lee SY AU - Nishida T AU - Ogawa W AU - Tobe K AU - Yamauchi T AU - Lim S AU - STEP 6 investigators PY - 2022 JO - The lancet. Diabetes & endocrinology DO - 10.1016/s2213-8587(22)00008-0 UR - https://doi.org/10.1016/s2213-8587(22)00008-0 ER -
APA
T, K., J, I., U, K., SY, L., T, N., W, O., K, T., T, Y., S, L., & investigators, S. 6. (2022). Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.. The lancet. Diabetes & endocrinology. https://doi.org/10.1016/s2213-8587(22)00008-0
Source records
- pubmed · retrieved 2026-09-26T01:52:21.247Z
- europe-pmc · retrieved 2026-09-26T01:52:21.253Z